Is it time for WebMD Health (WBMD) stock to break out? At least one analyst thinks so. Sandy Draper at SunTrust Robinson Humphrey has upgraded shares of the online medical information site to buy from neutral and raised his price target to 52 from 50. Draper sees the biopharmaceutical industry’s ad market — critical to WebMD’s success — growing by double digits and private portal growth boosting revenue over the next two years. He points out that
Online health-information provider WebMD (WBMD) on Monday raised its first-quarter and full-year financial guidance, and its temperature rose on the stock market today. WebMD stock was up 20%, near 45, in morning trading. That’s still 12% below a nearly three-year high of 51.41 touched on Feb. 19. The New York-based company said that it expects first-quarter and full-year results to exceed the midrange of its previously provided financial
Health-information website WebMD (WBMD) received a stock rating upgrade Monday on its improving mobile advertising prospects, but the Internet sector overall got a downgrade. Goldman Sachs analyst Health Terry raised his rating on WebMD to neutral from sell “based on recent signs that the company is beginning to monetize its mobile inventory with higher-value Pharma advertisers,” he wrote in a research note. But he downgraded several other